Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.
Recommended Dilutions: ELISA: 1:10,000-1:20,000; Immunohistochemsitry: 5 µg/mL; Immunofluorescence Microscopy: 20 ?g/mL; Western Blot: 1-2 ?g/mL; contains 0.02% (w/v) Sodium Azide
Type: Primary
Antigen: CALHM1
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope: N-Terminal
Host: Rabbit
Isotype: IgG1
Reactivity: Human, Mouse, Rat